Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: benzopyran-based therapeutics - Kazia Therapeutics

Next Previous
Drug Profile

Research programme: benzopyran-based therapeutics - Kazia Therapeutics

Alternative Names: CS-6; SBP therapeutics - Kazia Therapeutics; Super-benzopyran compounds - Kazia Therapeutics; Trilexium (Trx) analogues - Kazia Therapeutics; Trx-2 - Kazia Therapeutics; TRXE-0025; TRXE-009; TRXE-009-1; TRXE-025

Latest Information Update: 28 Mar 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novogen
  • Developer Kazia Therapeutics; Weill Cornell Medical College
  • Class Benzopyrans; Small molecules
  • Mechanism of Action Cell cycle inhibitors; EIF-2 kinase inhibitors; Electron transport chain complex protein inhibitors; Glucuronidase modulators; JNK mitogen-activated protein kinase modulators; NADH oxidase inhibitors; Stem cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease; Amyotrophic lateral sclerosis; Brain cancer; Brain disorders; Brain injuries; Facioscapulohumeral muscular dystrophy; Glioblastoma; Malignant melanoma; Mucopolysaccharidosis III; Neuroblastoma; Ovarian cancer; Prostate cancer

Most Recent Events

  • 28 Mar 2023 Discontinued - Preclinical for Glioblastoma in Australia (IV)
  • 28 Mar 2023 Discontinued - Preclinical for Glioblastoma in USA (IV)
  • 28 Mar 2023 Discontinued - Preclinical for Malignant melanoma in Australia (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top